Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 24 citations · 26 references
MedicinePharmacologyPharmacotherapyChemotherapyEpigeneticsMolecular OncologyCancer CytogeneticsChemotherapy In Hematologic MalignanciesHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentBortezomib-based RegimensCytogenetic AbnormalitiesDna Methylation ModulationDna MethyltransferasesLeukemia CytogeneticsRefractory Acute Myeloid Leukemia
We previously reported that bortezomib indirectly modulates transcription of DNA methyltransferase 1 (DNMT). We designed a phase I study of azacitidine (a direct DNMT inhibitor) plus bortezomib in acute myeloid leukemia (AML) to determine safety and tolerability. Twenty-three adults with relapsed/refractory AML received azacitidine 75 mg/m(2) daily on days 1-7. Bortezomib was dose escalated from 0.7 mg/m(2) on days 2 and 5 to 1.3 mg/m(2) on days 2, 5, 9 and 12. The target dose was reached without dose limiting toxicities. Infection and/or febrile neutropenia were frequent. Patients received a median of 2 cycles of therapy (range, 1-12+). Five of 23 patients achieved remission, including two with morphologic and cytogenetic complete response (CR) and three with CR and incomplete count recovery (CRi). Of CR/CRi responders with cytogenetic abnormalities at baseline, three of four achieved cytogenetic CR. The combination of azacitidine and bortezomib was tolerable and active in this cohort of poor-risk previously treated patients with AML.
26
Bruce D. Cheson, John M. Bennett, Thomas Büchner et al. · Journal of Clinical Oncology · 2003 · 2.7K citations
Medicine, Hematology, Oncology +17
Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations
Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · Journal of Clinical Oncology · 2009 · 958 citations · Full text
Medicine, Oncology, Pharmacology +13